Inventiva (NASDAQ:IVA) Stock Price Up 5.7% – Should You Buy?

by · The Cerbat Gem

Inventiva S.A. Sponsored ADR (NASDAQ:IVA – Get Free Report)’s stock price shot up 5.7% on Wednesday. The company traded as high as $3.39 and last traded at $3.4450. 666,986 shares changed hands during trading, a decline of 32% from the average daily volume of 977,604 shares. The stock had previously closed at $3.26.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on IVA shares. Weiss Ratings cut Inventiva from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, October 8th. Wall Street Zen raised shares of Inventiva from a “sell” rating to a “hold” rating in a research note on Saturday, October 3rd. Piper Sandler reiterated an “overweight” rating on shares of Inventiva in a report on Wednesday, September 16th. Cantor Fitzgerald assumed coverage on shares of Inventiva in a research report on Friday, July 17th. They set an “overweight” rating for the company. Finally, Guggenheim upped their target price on shares of Inventiva from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, September 15th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Inventiva has a consensus rating of “Buy” and a consensus target price of $15.86.

Get Our Latest Stock Analysis on IVA

Inventiva Trading Up 12.1%

The company has a 50-day moving average of $3.98 and a 200-day moving average of $4.43.

Inventiva (NASDAQ:IVA – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.14) EPS for the quarter. The company had revenue of $0.75 million during the quarter. As a group, research analysts forecast that Inventiva S.A. Sponsored ADR will post -0.81 EPS for the current year.

Institutional Trading of Inventiva

Institutional investors have recently made changes to their positions in the company. Platt Investment Counsel LLC purchased a new stake in shares of Inventiva in the third quarter valued at about $45,000. Engineers Gate Manager LP increased its stake in Inventiva by 155.5% in the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock valued at $269,000 after buying an additional 43,280 shares during the last quarter. Finally, Seven Fleet Capital Management LP purchased a new stake in Inventiva in the 1st quarter valued at about $1,111,000. Institutional investors own 19.06% of the company’s stock.

About Inventiva

(Get Free Report)

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva’s lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.

See Also